InNexus Biotechnology has developed a new antibody product from its DXL platform technology, DXL1218 (EGFR), for the potential treatment of colorectal cancer.     “Recent experimental data suggests that DXL1218 (EGFR) is superior to competing commercialized products on the market, such as Erbitux, in terms of potency and efficacy,” said Jeff Morhet, chief executive officer and chairman of InNexus. “I am very excited, as this latest development lends further support to the ro...